

Clinical trials of bivalirudin + eptifibatide

TrialResults-center www.trialresultscenter.org

1 percutaneous coronary intervention

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|---------------------------|
| bivalirudin + eptifibatide vs heparin + GP2b3a inhibitors | | | |
| Kleiman , 2002 n=NA follow-up: | bivalirudin + eptifibatide versus heparin + eptifibatide | patients who underwent elective percutaneous coronary intervention | Parallel groups open |

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>
- anticoagulant for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q388>

References

Kleiman, 2002:

Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T, Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002;143:585-93. [[11923794](#)]

Entry terms: bivalirudin, Hirulog-1 Hirulog Angiomax